Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Pukkala, EeroAndersen, Aage
Berglund, Göran
Gislefoss, Randi
Gudnason, Vilmundur
Hallmans, Göran
Jellum, Egil
Jousilahti, Pekka
Knekt, Paul
Koskela, Pentti
Kyyrönen, P Pentti
Lenner, Per
Luostarinen, Tapio
Löve, Arthur
Ogmundsdóttir, Helga
Stattin, Pär
Tenkanen, Leena
Tryggvadottir, Laufey
Virtamo, Jarmo
Wadell, Göran
Widell, Anders
Lehtinen, Matti
Dillner, Joakim
Issue Date
2007-04-23
Metadata
Show full item recordCitation
Acta Oncol 2007, 46(3):286-307Abstract
The Nordic countries have a long tradition of large-scale biobanking and comprehensive, population-based health data registries linkable on unique personal identifiers, enabling follow-up studies spanning many decades. Joint Nordic biobank-based studies provide unique opportunities for longitudinal molecular epidemiological research. The purpose of the present paper is to describe the possibilities for such joint studies, by describing some of the major Nordic biobank cohorts with a standardised calculation of the cancer incidence in these cohorts. Altogether two million donors have since 1966 donated more than four million biological samples, stored at -20 degrees C to -135 degrees C, to 17 biobank cohorts in Finland, Iceland, Norway and Sweden. As a result of joint database handling principles, the accuracy of personal identifiers and completeness of follow-up for vital status in all participating biobanks was improved. Thereafter, the cancer incidence was determined using follow-up through the national cancer registries. Biobanks based on random samples of population typically showed slightly lower cancer incidence rates than the general population, presumably due to better participation rates among health-conscious subjects. On the other hand, biobanks including samples for viral screening or clinical testing showed 1.5 to 2.1 fold increased incidence of cancer. This excess was very high immediately after sampling, but for some cancer sites remained elevated for years after clinical sampling. So far, more than 100 000 malignant neoplasms have occurred after sample donation, and the annual increase of the cancer cases in these cohorts is about 10 000. The estimates on the population-representativity of the biobanks will assist in interpretation of generalizability of results of future studies based on these samples, and the systematic tabulations of numbers of cancer cases will serve in study power estimations. The present paper summarizes optimal study designs of biobank-based studies of cancer.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldae974a485f413a2113503eed53cd6c53
10.1080/02841860701203545
Scopus Count
Collections
Related articles
- NORDCAN--a Nordic tool for cancer information, planning, quality control and research.
- Authors: Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, Køtlum JE, Olafsdóttir E, Pukkala E, Storm HH
- Issue date: 2010 Jun
- Trends in the overall survival of cancer patients diagnosed 1964-2003 in the Nordic countries followed up to the end of 2006: the importance of case-mix.
- Authors: Storm HH, Kejs AM, Engholm G, Tryggvadóttir L, Klint A, Bray F, Hakulinen T
- Issue date: 2010 Jun
- Ensuring quality in studies linking cancer registries and biobanks.
- Authors: Langseth H, Luostarinen T, Bray F, Dillner J
- Issue date: 2010 Apr
- Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods.
- Authors: Engholm G, Gislum M, Bray F, Hakulinen T
- Issue date: 2010 Jun